RU2017106159A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017106159A3 RU2017106159A3 RU2017106159A RU2017106159A RU2017106159A3 RU 2017106159 A3 RU2017106159 A3 RU 2017106159A3 RU 2017106159 A RU2017106159 A RU 2017106159A RU 2017106159 A RU2017106159 A RU 2017106159A RU 2017106159 A3 RU2017106159 A3 RU 2017106159A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14179732.4 | 2014-08-04 | ||
| EP14179732 | 2014-08-04 | ||
| PCT/EP2015/066999 WO2016020210A1 (en) | 2014-08-04 | 2015-07-24 | Csl behring gmbh |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017106159A RU2017106159A (ru) | 2018-09-06 |
| RU2017106159A3 true RU2017106159A3 (ru) | 2018-11-28 |
| RU2689338C2 RU2689338C2 (ru) | 2019-05-27 |
Family
ID=51298563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017106159A RU2689338C2 (ru) | 2014-08-04 | 2015-07-24 | Состав фактора viii |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10238718B2 (ru) |
| EP (1) | EP3177317B1 (ru) |
| JP (1) | JP6516829B2 (ru) |
| KR (1) | KR102192494B1 (ru) |
| CN (1) | CN106687126B (ru) |
| AU (1) | AU2015299224B2 (ru) |
| BR (1) | BR112017002090B1 (ru) |
| CA (1) | CA2956412A1 (ru) |
| DK (1) | DK3177317T3 (ru) |
| ES (1) | ES2788870T3 (ru) |
| IL (1) | IL250343B (ru) |
| MX (1) | MX2017000862A (ru) |
| NZ (1) | NZ729629A (ru) |
| PL (1) | PL3177317T3 (ru) |
| RU (1) | RU2689338C2 (ru) |
| SG (2) | SG10201900598TA (ru) |
| WO (1) | WO2016020210A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| WO2018101358A1 (ja) * | 2016-11-29 | 2018-06-07 | Ｓｐｉｂｅｒ株式会社 | タンパク質組成物、その製造方法及び熱安定性向上方法 |
| WO2018132874A1 (en) * | 2017-01-19 | 2018-07-26 | Csl Limited | Method of preventing an immune response with alpha- 1 anti-trypsin |
| CA3082043A1 (en) * | 2017-11-07 | 2019-05-16 | Rani Therapeutics, Llc | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
| CN113105562B (zh) * | 2018-09-26 | 2023-12-01 | 安源医药科技（上海）有限公司 | 突变型单链人凝血因子viii在制备融合蛋白中的应用 |
| CN112138149A (zh) * | 2019-06-28 | 2020-12-29 | 北京基科晟斯医药科技有限公司 | 重组凝血因子viii制剂 |
| CN116322920A (zh) | 2020-11-09 | 2023-06-23 | 武田药品工业株式会社 | 使用氧化硅吸附从血浆中纯化fviii |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| ES2097120T3 (es) | 1989-07-24 | 1997-04-01 | Bayer Ag | Estabilizacion de proteinas altamente purificadas. |
| DE4001451A1 (de) | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
| DE4111393A1 (de) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
| DE69333928T2 (de) | 1992-04-30 | 2006-08-17 | Probitas Pharma Inc., Los Angeles | Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes |
| JP3905921B2 (ja) | 1992-10-02 | 2007-04-18 | ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー | 凝固第▲ｖｉｉｉ▼因子を含む組成物及びその製造方法並びに安定剤としての界面活性剤の使用方法 |
| GB9501040D0 (en) | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
| SE9501189D0 (sv) | 1995-03-31 | 1995-03-31 | Pharmacia Ab | Protein formulation |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| PT2130554E (pt) | 1999-02-22 | 2012-11-19 | Univ Connecticut | Formulações de factor viii isentas de albumina |
| EP2292271A3 (en) | 2001-10-10 | 2011-09-14 | BioGeneriX AG | Remodelling and glycoconjugation of an antibody |
| GB0207092D0 (en) | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| AU2004298789A1 (en) * | 2003-12-19 | 2005-06-30 | Novo Nordisk Health Care Ag | Stabilised compositions of factor VII polypeptides |
| KR100624013B1 (ko) * | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
| US7523304B2 (en) * | 2005-11-22 | 2009-04-21 | Ntt Docomo, Inc. | Generation of set coverings with free riders, and generation of ordered sets of meeting points, in systems which include, but are not limited to, systems for broadcast encryption and systems for certificate revocation |
| RS52459B (en) | 2006-02-07 | 2013-02-28 | Shire Human Genetic Therapies Inc. | STABILIZED GLUCOCEREBROSIDASE COMPOSITIONS |
| TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| BRPI0708832A2 (pt) | 2006-03-31 | 2011-06-14 | Baxter Int | construÇço proteinÁcea |
| AU2007338298B2 (en) | 2006-12-22 | 2013-02-07 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| US8133865B2 (en) | 2006-12-27 | 2012-03-13 | Nektar Therapeutics | von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage |
| EP1988101A1 (en) | 2007-05-04 | 2008-11-05 | Novo Nordisk A/S | Improvement of factor VIII polypeptide titers in cell cultures |
| JP5323072B2 (ja) | 2007-07-11 | 2013-10-23 | ノボ・ノルデイスク・エー／エス | 混合方式又は多様式樹脂を使用する第ｖｉｉｉ因子の精製 |
| AU2008323768A1 (en) | 2007-11-09 | 2009-05-14 | Baxter Healthcare S.A. | Modified recombinant Factor VIII and von Willebrand Factor and methods of use |
| CN103497246B (zh) | 2008-02-27 | 2016-08-10 | 诺沃—诺迪斯克有限公司 | 缀合的因子viii分子 |
| AU2009289212B2 (en) * | 2008-09-03 | 2015-02-12 | Octapharma Ag | New protecting compositions for recombinantly produced factor VIII |
| SI2349342T1 (sl) | 2008-10-17 | 2018-10-30 | Baxalta GmbH | Modificirani krvni faktorji, ki obsegajo nizko stopnjo v vodi topnega polimera |
| US20100168018A1 (en) | 2008-11-07 | 2010-07-01 | Baxter International Inc. | Factor viii formulations |
| EP2398822B1 (en) | 2009-02-19 | 2013-01-02 | Novo Nordisk A/S | Modification of factor viii |
| ES2427627T3 (es) | 2009-04-06 | 2013-10-31 | Novo Nordisk A/S | Entrega dirigida de proteínas de Factor VIII a plaquetas |
| GB0915480D0 (en) | 2009-09-04 | 2009-10-07 | Arecor Ltd | Stable formulation of factor viii |
| JP5914363B2 (ja) | 2010-02-16 | 2016-05-11 | ノヴォ ノルディスク アー／エス | 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子 |
| CN102812039B (zh) | 2010-02-16 | 2016-01-20 | 诺沃—诺迪斯克有限公司 | 缀合蛋白质 |
| CN105153313A (zh) | 2010-02-16 | 2015-12-16 | 诺沃—诺迪斯克有限公司 | 因子viii融合蛋白 |
| EP2560686A2 (en) | 2010-04-21 | 2013-02-27 | Novo Nordisk A/S | Selective modification of proteins |
| EP2593130A2 (en) | 2010-07-15 | 2013-05-22 | Novo Nordisk A/S | Stabilized factor viii variants |
| SG188487A1 (en) | 2010-09-17 | 2013-05-31 | Baxter Int | Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph |
| KR20140084208A (ko) * | 2011-10-18 | 2014-07-04 | 시에스엘 리미티드 | 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법 |
| CN102580062B (zh) * | 2012-03-09 | 2017-03-08 | 中国医学科学院输血研究所 | 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂 |
| US20150080309A1 (en) * | 2012-04-24 | 2015-03-19 | Nova Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
| EP2882457A1 (en) * | 2012-08-13 | 2015-06-17 | Novo Nordisk A/S | Liquid factor viii formulations |
-
2015
- 2015-07-24 CA CA2956412A patent/CA2956412A1/en active Pending
- 2015-07-24 US US15/501,059 patent/US10238718B2/en active Active
- 2015-07-24 DK DK15741220.6T patent/DK3177317T3/da active
- 2015-07-24 KR KR1020177006119A patent/KR102192494B1/ko active IP Right Grant
- 2015-07-24 NZ NZ729629A patent/NZ729629A/en unknown
- 2015-07-24 SG SG10201900598TA patent/SG10201900598TA/en unknown
- 2015-07-24 WO PCT/EP2015/066999 patent/WO2016020210A1/en active Application Filing
- 2015-07-24 MX MX2017000862A patent/MX2017000862A/es unknown
- 2015-07-24 EP EP15741220.6A patent/EP3177317B1/en active Active
- 2015-07-24 AU AU2015299224A patent/AU2015299224B2/en active Active
- 2015-07-24 SG SG11201700550YA patent/SG11201700550YA/en unknown
- 2015-07-24 RU RU2017106159A patent/RU2689338C2/ru active
- 2015-07-24 PL PL15741220T patent/PL3177317T3/pl unknown
- 2015-07-24 BR BR112017002090-4A patent/BR112017002090B1/pt active IP Right Grant
- 2015-07-24 ES ES15741220T patent/ES2788870T3/es active Active
- 2015-07-24 CN CN201580041973.2A patent/CN106687126B/zh active Active
- 2015-07-24 JP JP2017506297A patent/JP6516829B2/ja active Active
-
2017
- 2017-01-30 IL IL250343A patent/IL250343B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| RU2689338C2 (ru) | 2019-05-27 |
| AU2015299224A1 (en) | 2017-03-23 |
| KR20170040327A (ko) | 2017-04-12 |
| CN106687126B (zh) | 2020-07-28 |
| KR102192494B1 (ko) | 2020-12-18 |
| IL250343B (en) | 2020-10-29 |
| BR112017002090B1 (pt) | 2021-06-01 |
| MX2017000862A (es) | 2017-05-01 |
| WO2016020210A8 (en) | 2016-04-28 |
| US10238718B2 (en) | 2019-03-26 |
| AU2015299224B2 (en) | 2019-06-20 |
| CN106687126A (zh) | 2017-05-17 |
| JP2017528440A (ja) | 2017-09-28 |
| NZ729629A (en) | 2021-12-24 |
| ES2788870T3 (es) | 2020-10-23 |
| PL3177317T3 (pl) | 2020-07-27 |
| JP6516829B2 (ja) | 2019-05-22 |
| US20170252412A1 (en) | 2017-09-07 |
| CA2956412A1 (en) | 2016-02-11 |
| WO2016020210A1 (en) | 2016-02-11 |
| SG10201900598TA (en) | 2019-02-27 |
| EP3177317B1 (en) | 2020-03-18 |
| BR112017002090A2 (pt) | 2018-01-30 |
| RU2017106159A (ru) | 2018-09-06 |
| SG11201700550YA (en) | 2017-02-27 |
| EP3177317A1 (en) | 2017-06-14 |
| DK3177317T3 (en) | 2020-06-15 |
| IL250343A0 (en) | 2017-03-30 |